MetaCap

Heron Therapeutics (HRTX) vs Verrica Pharmaceuticals (VRCA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Verrica Pharmaceuticals (VRCA) has outperformed Heron Therapeutics (HRTX) over the past year, losing 34.9% versus a loss of 76.2%. Over five years, HRTX leads with a -97.3% price change compared with -97.4% for VRCA. Heron Therapeutics is the larger company by market cap ($48.0 million vs $47.1 million), about 1.0 times the size, while Verrica Pharmaceuticals is growing revenue faster (+370.2% vs +7.4%).

Heron Therapeutics converts more of its revenue into profit, with a net margin of -13.0% versus -50.3%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

HRTX-76.18%VRCA-34.92%
+126%+20%-86%
Nov 21, 20251 yearNov 20, 2026
HRTX-97.51%VRCA-97.60%
+5%-49%-102%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

HRTX versus VRCA key metrics
MetricHRTXVRCA
Share price$0.2525$2.74
Market cap$48.04M$47.07M
1-day change-4.39%-5.03%
YTD return-80.58%-67.03%
1-year return-76.18%-34.92%
5-year return-97.32%-97.38%
EPS (TTM)$-0.11$-2.30
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$154.90M$35.58M
Revenue growth (YoY)+7.36%+370.22%
Net income (latest FY)$-20.20M$-17.89M
Gross margin73.31%—
Operating margin-1.64%-34.25%
Net margin-13.04%-50.27%
52-week high$1.58$9.82
52-week low$0.2479$2.73
Distance from 52-week high-84.02%-72.10%
Analyst consensusnonestrong_buy
Avg. price target upside+2672.28%+404.74%
Average volume4.56M68.78K
Shares outstanding190.27M17.18M
Employees12876
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • VRCA has outperformed HRTX by 41.3 percentage points over the past year.
  • Heron Therapeutics is more profitable, keeping -13.0 cents of every revenue dollar as net income versus -50.3 cents for Verrica Pharmaceuticals.
  • Verrica Pharmaceuticals grew revenue faster in its latest fiscal year (+370.22% vs +7.36%).

About Heron Therapeutics

HRTX stock →

Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees

About Verrica Pharmaceuticals

VRCA stock →

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts.

Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees

HRTX vs VRCA FAQ

Which is bigger, Heron Therapeutics or Verrica Pharmaceuticals?

Heron Therapeutics (HRTX) is larger, with a market capitalization of $48.04M compared with $47.07M for Verrica Pharmaceuticals (VRCA).

Which stock has performed better over the past year, HRTX or VRCA?

VRCA returned -34.92% over the past 12 months, compared with -76.18% for HRTX (price return, excluding dividends). Past performance does not predict future results.

Are Heron Therapeutics and Verrica Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons